Jupiter Neurosciences wins exclusive U.S. rights to ALA-002

Jupiter Neurosciences said July 22 it signed a definitive license agreement for perpetual exclusive U.S. rights to ALA-002, a patented MDMA formulation with FDA Novel Chemical Entity designation. The deal could be worth up to $100 million and gives the Nasdaq-listed biotech a second clinical-stage CNS asset alongside its Parkinson’s program.

Why it matters: - The deal moves Jupiter Neurosciences from a single-program company to a dual clinical-stage central nervous system developer. - Jupiter gains a second asset with U.S. commercialization potential while its lead Parkinson’s program continues. - The transaction adds diversification for a small biotech that is still exposed to clinical, regulatory and financing risk.

What happened: - Jupiter Neurosciences entered a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002. - The company announced the deal on July 22, 2026. - The transaction has a potential value of up to $100 million, including milestone payments, excluding ongoing royalties. - Jupiter says the agreement expands the company from a single-program platform into a dual clinical-stage CNS developer.

The details: - Jupiter will pay $3.3 million upfront, including $1.5 million in cash and $1.8 million in JUNS common stock subject to a 120-day lock-up. - PharmAla can receive a $3.3 million development milestone if ALA-002 reaches Phase 3 first patient in. - A $20 million regulatory milestone is due upon U.S. NDA approval. - Commercial milestones are set at $10 million, $30 million and $33.3 million when cumulative U.S. net sales hit $333 million, $1 billion and $2 billion. - Royalty payments of 3% of net sales begin after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation with FDA Novel Chemical Entity designation. - The designation provides enhanced regulatory protection and a five-year data exclusivity period upon approval. - The rights are perpetual and exclusive to the United States. - PharmAla will continue manufacturing ALA-002 drug product for Jupiter under commercial terms to be negotiated. - Jupiter said the arrangement could accelerate development timelines because PharmAla already supplies MDMA for clinical use. - PharmAla’s MDMA supply is active in U.S. government-sponsored VA and DHA clinical trials. - Jupiter’s lead program, JOTROL™, is a proprietary enhanced-bioavailability resveratrol formulation in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia™, a consumer longevity supplement. - Jupiter is a B2i Digital Featured Company. More information

Between the lines: - The acquisition gives Jupiter exposure to the psychedelic therapeutics space at a time when federal policy is moving to speed investigational treatment pathways. - On April 18, 2026, President Donald J. Trump signed an executive order directing the FDA and DEA to expand access to investigational psychedelic therapies. - The order includes a Right to Try pathway, Commissioner’s National Priority Vouchers for faster FDA review and $50 million in federal ARPA-H funding. - Management believes the new U.S. rights position Jupiter to benefit from that regulatory backdrop. - Jupiter’s comments also point to a broader strategic shift toward CNS and brain plasticity. - Alison Silva said the company has added new board experts, including Drs. Tomas Philipson and Andrew Cutler.

What’s next: - Jupiter will move toward development execution on both ALA-002 and JOTROL™. - The company’s next value inflection points include clinical progress, regulatory milestones and potential U.S. commercialization. - PharmAla will continue advancing ALA-002 outside the United States. - Jupiter said the next 12 months will be transformative for the company.

The bottom line: - Jupiter is buying optionality in CNS drugs and psychedelics with a deal that could reshape its pipeline, but the value still depends on clinical success, regulatory approvals and capital discipline.